 |
48 Diseases |  |
1 Trial |
|
1 Trial |  |
23 News |  |
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis (clinicaltrials.gov) - Dec 1, 2022
P3, N=40, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting
- |||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis (clinicaltrials.gov) - Jan 4, 2022
P3, N=40, Not yet recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Italy set to renew tax scheme to spur investment https://t.co/B1UnPb001t (Twitter) - Oct 7, 2019
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Apr 12, 2017
P2, N=7, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial initiation date: Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barr (clinicaltrials.gov) - Apr 11, 2017
P3, N=22, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015 Recruiting --> Completed | Initiation date: Apr 2014 --> Oct 2014
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Enrollment change, Trial primary completion date: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. (clinicaltrials.gov) - Jan 20, 2016
P3, N=13, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed | Initiation date: Apr 2014 --> Oct 2014 Enrolling by invitation --> Completed | N=10 --> 13 | Trial primary completion date: Sep 2015 --> Jun 2015
- || Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Jan 20, 2016
P3, N=49, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Enrolling by invitation --> Completed | N=10 --> 13 | Trial primary completion date: Sep 2015 --> Jun 2015 Enrolling by invitation --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jun 12, 2015
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Enrolling by invitation --> Completed Trial primary completion date: Mar 2015 --> Dec 2015
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Oct 17, 2014
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Mar 2015 --> Dec 2015 Trial primary completion date: Mar 2014 --> Mar 2015
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment status, Trial primary completion date: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. (clinicaltrials.gov) - Oct 17, 2014
P3, N=10, Enrolling by invitation, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment status, Trial primary completion date: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Oct 17, 2014
P3, N=48, Enrolling by invitation, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015 Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015
- ||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barr (clinicaltrials.gov) - Aug 21, 2014
P3, N=21, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Enrolling by invitation | Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Jan 2014 --> Jun 2014
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014
- ||||||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion: Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids (clinicaltrials.gov) - Oct 14, 2013
P3, N=56, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Completed
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jul 9, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Completed Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. (clinicaltrials.gov) - Jul 9, 2013
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Jul 9, 2013
P3, N=48, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P2 trial: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - May 1, 2013
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. (clinicaltrials.gov) - Apr 7, 2013
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- ||| Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. (clinicaltrials.gov) - Apr 2, 2013
P3, N=48, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Enrollment open: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Dec 17, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
New P3 trial: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Sep 27, 2012
P3, N=10, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd